Larvol Delta - Marker-Therapeutics-Awarded-2-Million-Grant-from-NIH-in-Support-of-Phase-1-Study-Investigating-MT601-in-CARRelapsed-Patients-with-NonHodgkins-Lymphoma

neldaleucel (MT-601) - Marker Therap

https://www.globenewswire.com/news-release/2024/08/12/2928275/0/en/Marker-Therapeutics-Awarded-2-Million-Grant-from-NIH-in-Support-of-Phase-1-Study-Investigating-MT-601-in-CAR-Relapsed-Patients-with-Non-Hodgkin-s-Lymphoma.html

Aug 12, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next